

Martin J Brodie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8033907/publications.pdf>

Version: 2024-02-01

77
papers

15,212
citations

81900

39
h-index

71685

76
g-index

77
all docs

77
docs citations

77
times ranked

10810
citing authors

#	ARTICLE	IF	CITATIONS
1	Markov modelling of treatment response in a 30-year cohort study of newly diagnosed epilepsy. <i>Brain</i> , 2022, 145, 1326-1337.	7.6	3
2	High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. <i>Epilepsia</i> , 2022, 63, e1.	5.1	17
3	ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. <i>Epilepsia</i> , 2022, 63, 316-334.	5.1	28
4	Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COVE study. <i>Epilepsy and Behavior</i> , 2021, 115, 107658.	1.7	37
5	Adjunctive brivaracetam – A prospective audit of outcomes from an epilepsy clinic. <i>Epilepsy and Behavior</i> , 2021, 116, 107746.	1.7	5
6	The road to a World Health Organization global action plan on epilepsy and other neurological disorders. <i>Epilepsia</i> , 2021, 62, 1057-1063.	5.1	27
7	Impact of the COVID-19 pandemic on people with epilepsy: Findings from the Brazilian arm of the COVE study. <i>Epilepsy and Behavior</i> , 2021, 123, 108261.	1.7	8
8	Characteristics and treatment outcomes of newly diagnosed epilepsy in older people: A 30-year longitudinal cohort study. <i>Epilepsia</i> , 2020, 61, 2720-2728.	5.1	14
9	30 years of second-generation antiseizure medications: impact and future perspectives. <i>Lancet Neurology</i> , The, 2020, 19, 544-556.	10.2	134
10	Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy. <i>JAMA Neurology</i> , 2020, 77, 574.	9.0	41
11	Keeping people with epilepsy safe during the COVID-19 pandemic. <i>Neurology</i> , 2020, 94, 1032-1037.	1.1	116
12	Pharmacological outcomes in teenagers with newly diagnosed epilepsy: A 30-year cohort study. <i>Epilepsia</i> , 2019, 60, 1083-1090.	5.1	11
13	Management of epilepsy in women. <i>Lancet Neurology</i> , The, 2019, 18, 481-491.	10.2	86
14	Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs. <i>JAMA Neurology</i> , 2018, 75, 279.	9.0	910
15	Commonalities in epileptogenic processes from different acute brain insults: Do they translate?. <i>Epilepsia</i> , 2018, 59, 37-66.	5.1	206
16	Brivaracetam: a novel antiepileptic drug for focal-onset seizures. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561774208.	3.5	39
17	Cannabinoids for epilepsy: What do we know and where do we go?. <i>Epilepsia</i> , 2018, 59, 291-296.	5.1	32
18	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. <i>Epilepsia</i> , 2018, 59, 1727-1739.	5.1	67

#	ARTICLE	IF	CITATIONS
19	Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. <i>Epilepsy and Behavior</i> , 2017, 71, 73-78.	1.7	77
20	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. <i>Journal of Clinical Investigation</i> , 2017, 127, 2118-2132.	8.2	90
21	Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. <i>Pharmacological Reviews</i> , 2016, 68, 563-602.	16.0	186
22	Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy. <i>Epilepsy and Behavior</i> , 2016, 54, 100-103.	1.7	34
23	Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. <i>Epilepsy Research</i> , 2016, 119, 62-66.	1.6	39
24	Prospective audits with newer antiepileptic drugs in focal epilepsy: Insights into population responses?. <i>Epilepsy and Behavior</i> , 2014, 31, 73-76.	1.7	33
25	Adjunctive lacosamideâ€™5 Yearsâ€™™ clinical experience. <i>Epilepsy Research</i> , 2014, 108, 1385-1391.	1.6	31
26	Enzyme induction with antiepileptic drugs: Cause for concern?. <i>Epilepsia</i> , 2013, 54, 11-27.	5.1	293
27	Drug-Resistant Epilepsy. <i>New England Journal of Medicine</i> , 2011, 365, 919-926.	27.0	959
28	Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2010, 51, 1069-1077.	5.1	3,400
29	A prospective audit of adjunctive zonisamide in an everyday clinical setting. <i>Epilepsy and Behavior</i> , 2010, 17, 455-460.	1.7	31
30	Epilepsy in later life. <i>Lancet Neurology</i> , The, 2009, 8, 1019-1030.	10.2	269
31	Selection of Antiepileptic Drugs in Adults. <i>Neurologic Clinics</i> , 2009, 27, 967-992.	1.8	25
32	Should all patients be told about sudden unexpected death in epilepsy (SUDEP)? Pros and Cons. <i>Epilepsia</i> , 2008, 49, 99-101.	5.1	54
33	Outcomes in Elderly Patients With Newly Diagnosed and Treated Epilepsy. <i>International Review of Neurobiology</i> , 2007, 81, 253-263.	2.0	30
34	Pharmacokinetics and Drug Interactions with Zonisamide. <i>Epilepsia</i> , 2007, 48, 435-441.	5.1	88
35	Pharmacological outcomes in older people with newly diagnosed epilepsy. <i>Epilepsy and Behavior</i> , 2006, 8, 434-437.	1.7	57
36	Response to Antiepileptic Drug Therapy: Winners and Losers. <i>Epilepsia</i> , 2005, 46, 31-32.	5.1	19

#	ARTICLE	IF	CITATIONS
37	Dose-dependent Safety and Efficacy of Zonisamide: A Randomized, Double-blind, Placebo-controlled Study in Patients with Refractory Partial Seizures. <i>Epilepsia</i> , 2005, 46, 31-41.	5.1	238
38	Epilepsy in elderly people. <i>BMJ: British Medical Journal</i> , 2005, 331, 1317-1322.	2.3	152
39	Pharmacological outcomes in newly diagnosed epilepsy. <i>Epilepsy and Behavior</i> , 2005, 6, 382-387.	1.7	67
40	Levetiracetam in refractory epilepsy: a prospective observational study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2005, 14, 23-27.	2.0	44
41	Zonisamide clinical trials: European experience. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2004, 13, S66-S70.	2.0	32
42	EUCAREâ€”past, present, and future. <i>Lancet Neurology</i> , The, 2003, 2, 269.	10.2	1
43	Building New Understandings in Epilepsy: Maximizing Patient Outcomes Without Sacrificing Seizure Control. <i>Epilepsia</i> , 2003, 44, 1-2.	5.1	6
44	Building new understandings in epilepsy: maximizing patient outcomes without sacrificing seizure control. <i>Epilepsia</i> , 2003, 44 Suppl 4, 1-2.	5.1	1
45	Role of levetiracetam in the treatment of epilepsy. <i>Epileptic Disorders</i> , 2003, 5 Suppl 1, S65-72.	1.3	1
46	Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. <i>Epilepsy and Behavior</i> , 2002, 3, 140-146.	1.7	37
47	Gabapentin versus Lamotrigine Monotherapy: A Double-blind Comparison in Newly Diagnosed Epilepsy. <i>Epilepsia</i> , 2002, 43, 993-1000.	5.1	104
48	Staged approach to epilepsy management. <i>Neurology</i> , 2002, 58, S2-8.	1.1	214
49	To the Editor. <i>Epilepsy and Behavior</i> , 2001, 2, 616.	1.7	0
50	The Star Systems. <i>CNS Drugs</i> , 2001, 15, 1-12.	5.9	52
51	Hormone Profiles in Young Adults with Epilepsy Treated with Sodium Valproate or Lamotrigine Monotherapy. <i>Epilepsia</i> , 2001, 42, 1002-1006.	5.1	95
52	Development and Validation of the Glasgow Epilepsy Outcome Scale (GEOS): A New Instrument for Measuring Concerns about Epilepsy in People with Mental Retardation. <i>Epilepsia</i> , 2001, 42, 1043-1051.	5.1	39
53	Management Strategies for Refractory Localization-Related Seizures. <i>Epilepsia</i> , 2001, 42, 27-30.	5.1	38
54	Effectiveness of First Antiepileptic Drug. <i>Epilepsia</i> , 2001, 42, 1255-1260.	5.1	372

#	ARTICLE	IF	CITATIONS
55	Does the Cause of Localisation-Related Epilepsy Influence the Response to Antiepileptic Drug Treatment?. <i>Epilepsia</i> , 2001, 42, 357-362.	5.1	227
56	Topiramate in Refractory Epilepsy: A Prospective Observational Study. <i>Epilepsia</i> , 2000, 41, 977-980.	5.1	82
57	Concentration-Effect Studies with Topiramate on Selected Enzymes and Intermediates of the GABA Shunt. <i>Epilepsia</i> , 2000, 41, 30-34.	5.1	127
58	Early Identification of Refractory Epilepsy. <i>New England Journal of Medicine</i> , 2000, 342, 314-319.	27.0	4,264
59	Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. <i>Epilepsy Research</i> , 1999, 37, 81-87.	1.6	431
60	Lamotrigine-Associated Rash: Risk/Benefit Considerations in Adults and Children. <i>Epilepsia</i> , 1999, 40, 985-991.	5.1	310
61	Monostars: An Aid to Choosing an Antiepileptic Drug as Monotherapy. <i>Epilepsia</i> , 1999, 40, s17-s22.	5.1	27
62	Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. <i>British Journal of Pharmacology</i> , 1999, 126, 1634-1638.	5.4	47
63	Adenosine monophosphate as a mediator of ATP effects at P1 purinoceptors. <i>British Journal of Pharmacology</i> , 1998, 124, 818-824.	5.4	17
64	Tiagabine in the Management of Epilepsy. <i>Epilepsia</i> , 1997, 38, S23.	5.1	21
65	The Teenagers' Service: An Evaluation of Epilepsy Care. <i>Epilepsia</i> , 1997, 38, S5.	5.1	4
66	Neurochemical actions of the desglycyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. <i>British Journal of Pharmacology</i> , 1997, 121, 923-926.	5.4	7
67	Lamotrigine - An Update. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, S6-S9.	0.5	32
68	Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites. <i>Epilepsia</i> , 1996, 37, 1100-1106.	5.1	21
69	Tiagabine Pharmacology in Profile. <i>Epilepsia</i> , 1995, 36, S7-S9.	5.1	80
70	How Common Is Catamenial Epilepsy?. <i>Epilepsia</i> , 1993, 34, 827-831.	5.1	111
71	Pharmacokinetic Optimisation of Anticonvulsant Therapy. <i>Clinical Pharmacokinetics</i> , 1992, 23, 216-230.	3.5	52
72	Drug Interactions in Epilepsy. <i>Epilepsia</i> , 1992, 33, S13-22.	5.1	80

#	ARTICLE	IF	CITATIONS
73	Nifedipine for Epilepsy? A Double-Blind, Placebo-Controlled Trial. <i>Epilepsia</i> , 1992, 33, 346-352.	5.1	26
74	Lack of Major Effects on Mouse Brain Adenosine A ₁ Receptors of Oral Carbamazepine and Calcium Antagonists. <i>Epilepsia</i> , 1991, 32, 729-734.	5.1	6
75	Drug Interactions that Matter. <i>Drugs</i> , 1988, 36, 83-110.	10.9	99
76	Circulating Hormones and Pituitary Responsiveness in Young Epileptic Men Receiving Long-Term Antiepileptic Medication. <i>Epilepsia</i> , 1988, 29, 468-475.	5.1	108
77	Intradose and Circadian Variation in Circulating Carbamazepine and Its Epoxide in Epileptic Patients: A Consequence of Autoinduction of Metabolism. <i>Epilepsia</i> , 1987, 28, 286-294.	5.1	44